Curing chronic hepatitis C - The arc of a medical triumph

New England Journal of Medicine

Volumn 370, Issue 17, 2014, Pages 1576-1578

  Chung, Raymond T ^a   Baumert, Thomas F ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NONNUCLEOSIDE INHIBITOR; NS5A INHIBITOR; NUCLEOSIDE INHIBITOR; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; UNCLASSIFIED DRUG;

DRUG SCREENING; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION; LIFE CYCLE; MEDICAL RESEARCH; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK REDUCTION; SHORT SURVEY; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS GENOME; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NUCLEOSIDES;

EID: 84899101946     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1400986     Document Type: Article

References (5)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62. (Pubitemid 19117877)
2. Scheel TKH, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013;19:837-49.
3. Schaefer EAK, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterology 2012;142(6):1340.e1-1350.e1.
4. Ghany MG, Liang TJ. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013;369:679-80.
5. Zeisel MB, Lupberger J, Fofana I, Baumert TF. Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. J Hepatol 2013;58:375-84.